Prevalence_NN of_IN Protease_NP and_CC Reverse_NP Transcriptase_NP Drug_NP Resistance_NP Mutations_NP over_IN Time_NP in_IN Drug-Naive_NP Human_NP Immunodeficiency_NN Virus_NP Type_NP 1-Positive_JJ Individuals_NNS in_IN Rio_NP de_NP Janeiro_NP ,_, Brazil_NP The_DT prevalence_NN of_IN mutations_NNS that_WDT confer_VBP resistance_NN to_TO protease_NN inhibitors_NNS and_CC to_TO nucleoside_NN and_CC nonnucleoside_JJ reverse_JJ transcriptase_NN inhibitors_NNS in_IN 49_CD blood_NN samples_NNS from_IN drug-naive_JJ human_JJ immunodeficiency_NN virus_NN type_NN 1-infected_JJ blood_NN donors_NNS living_VBG in_IN Rio_NP de_NP Janeiro_NP state_NN ,_, Brazil_NP ,_, in_IN 1998_CD was_VBD evaluated_VBN genotypically_RB and_CC phenotypically_RB ._SENT The_DT new_JJ generation_NN of_IN drugs_NNS targeting_VBG the_DT reverse_JJ transcriptase_NN (_( RT_NP )_) and_CC protease_NN (_( PR_NP )_) genes_NNS of_IN the_DT pol_NN region_NN of_IN human_JJ immunodeficiency_NN virus_NN type_NN 1_CD (_( HIV-1_NP )_) ,_, such_JJ as_IN nucleoside_NN reverse_JJ transcriptase_NN inhibitors_NNS (_( NRTIs_NP )_) ,_, nonnucleoside_JJ reverse_JJ transcriptase_NN inhibitors_NNS (_( NNRTIs_NP )_) ,_, and_CC protease_NN inhibitors_NNS (_( PIs_NP )_) ,_, has_VBZ revolutionized_VBN treatment_NN of_IN infected_JJ individuals_NNS ._SENT However_RB ,_, not_RB all_DT patients_NNS respond_VB to_TO highly_RB active_JJ antiretroviral_JJ treatment_NN (_( HAART_NP )_) ,_, and_CC many_RB develop_VB drug_NN resistance_NN ,_, one_CD of_IN the_DT most_RBS serious_JJ obstacles_NNS to_TO sustained_JJ suppression_NN of_IN HIV-1_NP The_DT emergence_NN of_IN amino_NN acid_NN mutations_NNS associated_VBN with_IN resistance_NN to_TO RTIs_NP and_CC PIs_NP has_VBZ been_VBN extensively_RB characterized_VBN ,_, and_CC these_DT substitutions_NNS can_MD be_VB classified_VBN into_IN primary_JJ and_CC secondary_JJ mutations_NNS ._SENT Primary_JJ mutations_NNS lead_VBP to_TO a_DT severalfold_JJ decrease_NN in_IN sensitivity_NN to_TO one_CD or_CC more_JJR antiretroviral_NN (_( ARV_NP )_) drugs_NNS ._SENT Secondary_JJ mutations_NNS may_MD not_RB result_VB in_IN a_DT significant_JJ decrease_NN in_IN drug_NN sensitivity_NN but_CC are_VBP associated_VBN with_IN restoration_NN of_IN the_DT original_JJ viral_JJ fitness_NN in_IN the_DT presence_NN of_IN existing_VBG inhibitors_NNS ._SENT The_DT transmission_NN and_CC dissemination_NN of_IN drug-resistant_JJ strains_NNS have_VBP major_JJ public_JJ health_NN implications_NNS ,_, including_VBG disrupting_VBG the_DT efficiency_NN of_IN established_JJ ARV_NP treatment_NN for_IN HIV-1-infected_JJ patients_NNS and_CC of_IN prophylaxis_NN against_IN both_DT accidental_JJ exposures_NNS and_CC perinatal_JJ HIV-1_JJ transmission_NN ._SENT Prevalences_NNS of_IN primary_JJ resistance_NN mutations_NNS for_IN any_DT drug_NN observed_VBD among_IN recent_JJ seroconverters_NNS range_VBP from_IN 5_CD to_TO 11_CD %_NN in_IN Switzerland_NP (_( ;_: S._NP Yerly_NP ,_, E._NP Race_NP ,_, S._NP Vora_NP ,_, P._NP Rizzardi_NP ,_, J._NP P._NP Chave_NP ,_, M._NP Flepp_NP ,_, P._NP Vernazza_NP ,_, A._NP Telenti_NP ,_, M._NP Battegay_NP ,_, A._NP L._NP Veuthey_NP ,_, B._NP Hirschel_NP ,_, L._NP Perrin_NP ,_, and_CC the_DT Swiss_NP HIV_NP Cohort_NP Study_NP ,_, Program_NP Abstr_NP ._SENT 8th_JJ Conf_NP ._SENT Retroviruses_NNS Opportunistic_JJ Infections_NNS ,_, abstr_NN ._SENT 754_CD ,_, 2001_CD )_) ,_, 4_CD to_TO 17_CD %_NN in_IN France_NP (_( ,_, ;_: M._NP L._NP Chaix_NP ,_, M._NP Harzic_NP ,_, B._NP Masquelier_NP ,_, I._NP Pellegrin_NP ,_, L._NP Meyer_NP ,_, D._NP Costagliola_NP ,_, C._NP Rouzioux_NP ,_, and_CC F._NP Brun-Vezinet_NP ,_, Program_NP Abstr_NP ._SENT 8th_JJ Conf_NP ._SENT Retroviruses_NNS Opportunistic_JJ Infections_NNS ,_, abstr_NN ._SENT 755_CD ,_, 2001_CD )_) ,_, 13_CD %_NN in_IN Germany_NP ,_, 14_CD %_NN in_IN the_DT United_NP Kingdom_NP ,_, 2_CD to_TO 26_CD %_NN in_IN North_NP America_NP [_SYM ,_, ,_, ,_, ,_, ;_: S._NP J._NP Little_NP ,_, S._NP Holte_NP ,_, and_CC J._NP P._NP Routy_NP ,_, abstract_JJ from_IN 5th_JJ Int_NP ._SENT Workshop_NN HIV_NP Drug_NP Resist_NP ._SENT Treatment_NP Strategies_NP ,_, 4_CD to_TO 8_CD June_NP 2001_CD ,_, Scottsdale_NP ,_, Ariz._NP Antivir_NP ._SENT Ther_NNS ._SENT 6(Suppl_JJ ._SENT 1):21_JJ ,_, 2001_CD ]_SYM ,_, and_CC 23_CD to_TO 26_CD %_NN in_IN Spain_NP ._SENT Information_NN on_IN PI-_NP and_CC RTI-associated_NP mutations_NNS in_IN HIV-1-infected_JJ drug-naive_JJ individuals_NNS in_IN Brazil_NP is_VBZ limited_VBN to_TO specimens_NNS collected_VBN before_IN 1996_CD ,_, when_WRB free_JJ access_NN to_TO HAART_NP was_VBD established_VBN for_IN AIDS_NP patients_NNS by_IN the_DT Brazilian_JJ Ministry_NP of_IN Health_NP ._SENT These_DT specimens_NNS have_VBP shown_VBN a_DT low_JJ prevalence_NN of_IN mutations_NNS related_VBN to_TO NRTIs_NP ,_, NNRTIs_NP ,_, and_CC PIs_NP ._SENT In_IN this_DT paper_NN ,_, we_PP describe_VBP the_DT genetic_JJ diversity_NN of_IN HIV-1_NP PR_NP and_CC RT_NP sequences_NNS and_CC the_DT prevalence_NN of_IN mutations_NNS linked_VBN to_TO PI_NP and_CC RTI_NP resistance_NN in_IN treatment-naive_JJ HIV-1-infected_JJ blood_NN donors_NNS living_VBG in_IN the_DT state_NN of_IN Rio_NP de_NP Janeiro_NP ,_, Brazil_NP ,_, in_IN 1998_CD ._SENT Of_IN the_DT 18,667_CD blood_NN units_NNS collected_VBN from_IN January_NP through_IN December_NP 1998_CD at_IN blood_NN banks_NNS distributed_VBN throughout_IN the_DT state_NN of_IN Rio_NP de_NP Janeiro_NP ,_, 56_CD were_VBD rejected_VBN based_VBN on_IN their_PP$ HIV-1_JJ positivity_NN by_IN enzyme_NN immunoassay_NN (_( Prism_NP HIV-1/HIV-2_NP [_SYM Abbott_NP ,_, North_NP Chicago_NP ,_, Ill._NP ]_SYM and_CC Vironostika_NP HIV_NP Uni-Form_NP plus_IN O_NP [_SYM Organon_NP Teknika_NP BV_NP ,_, Boxtel_NP ,_, The_DT Netherlands_NPS ]_SYM )_) ._SENT After_IN confirmation_NN by_IN Western_JJ blot_NN analysis_NN ,_, the_DT viral_JJ RNA_NP was_VBD isolated_VBN from_IN plasma_NN ,_, and_CC PR_NP and_CC RT_NP genes_NNS were_VBD RT-PCR_NP amplified_VBN and_CC sequenced_VBN as_IN previously_RB described_VBN ._SENT This_DT study_NN was_VBD approved_VBN by_IN the_DT Brazilian_JJ Ethics_NP Committee_NP (_( CONEP_NP )_) as_IN an_DT anonymous_JJ unlinked_JJ study_NN ._SENT Phylogenetic_JJ analysis_NN was_VBD performed_VBN using_VBG the_DT neighbor-joining_JJ method_NN as_IN previously_RB described_VBN ._SENT Of_IN 44_CD samples_NNS positive_JJ for_IN both_DT PR_NP and_CC RT_NP sequences_NNS ,_, 40_CD had_VBD concordant_JJ subtype_NN assignments_NNS in_IN these_DT regions_NNS ,_, including_VBG 39_CD (_( 89_CD %_NN )_) subtype-B_NN specimens_NNS and_CC 1_CD (_( 2_CD %_NN )_) subtype-C_NN specimen_NN ._SENT The_DT remaining_VBG four_CD samples_NNS revealed_VBD discordant_JJ subtypes_NNS for_IN the_DT PR_NP and_CC RT_NP regions_NNS ,_, which_WDT may_MD represent_VB recombinant_JJ viruses_NNS ._SENT Finally_RB ,_, of_IN the_DT five_CD specimens_NNS with_IN HIV-1_JJ subtype_NN assignment_NN for_IN only_RB one_CD viral_JJ region_NN ,_, two_CD PR_NP and_CC two_CD RT_NP sequences_NNS were_VBD of_IN subtype_NN B_NN and_CC one_CD RT_NP sequence_NN was_VBD of_IN subtype_NN F._NP These_DT results_NNS indicate_VBP that_IN subtype_NN distributions_NNS in_IN our_PP$ sampling_NN reflect_VB the_DT proportions_NNS previously_RB observed_VBD in_IN Brazil_NP ._SENT TABLE_NN 1_CD |_SYM Presence_NN of_IN PR_NP and_CC RT_NP inhibitor-associated_VBD mutations_NNS in_IN subtype-B_NN and_CC non-B_NN Brazilian_JJ HIV-1_NP strains_NNS collected_VBN in_IN 1998_CD To_TO examine_VB the_DT frequency_NN of_IN primary_JJ (_( D30N_NP ,_, M46I_NP ,_, G48V_NP ,_, I50V_NP ,_, V82A_NP ,_, -F_NN ,_, or_CC T_NN [_SYM V82A/F/T_NP ]_SYM ,_, I84V_NP ,_, and_CC L90_NP M_NP )_) and_CC secondary_JJ (_( L10I/R/V_NP ,_, K20M/R_NP ,_, L24I_NP ,_, V32I_NP ,_, L33F_NP ,_, M36I_NP ,_, M46I/L_NP ,_, I47V_NP ,_, I54L/M/V_NP ,_, L63P_NP ,_, A71V/T_NP ,_, G73S_NP ,_, V77I_NP ,_, V82I_NP ,_, and_CC N88D_JJ )_) PI-associated_JJ substitutions_NNS within_IN the_DT PR_NP region_NN ,_, we_PP analyzed_VBD these_DT 20_CD amino_NN acid_NN sites_NNS ,_, which_WDT are_VBP associated_VBN in_IN vivo_JJ with_IN resistance_NN in_IN HIV-1_JJ subtype_NN B_NN to_TO PIs_NP approved_VBN by_IN the_DT U.S._NP Food_NP and_CC Drug_NP Administration_NP (_( FDA_NP )_) ._SENT This_DT analysis_NN revealed_VBD a_DT lack_NN of_IN primary_JJ substitutions_NNS in_IN 46_CD PR_NP sequences_NNS ._SENT However_RB ,_, secondary_JJ mutations_NNS were_VBD found_VBN in_IN 39_CD (_( 85_CD %_NN )_) of_IN the_DT 46_CD viral_JJ sequences_NNS at_IN six_CD positions_NNS ._SENT L63P_NP was_VBD the_DT most_RBS common_JJ secondary_JJ substitution_NN (_( 54_CD %_NN ;_: 25_CD of_IN 46_CD )_) ,_, followed_VBN by_IN V77I_NP (_( 26_CD %_NN ;_: 12_CD of_IN 46_CD )_) ,_, M36I_NP (_( 20_CD %_NN ;_: 9_CD of_IN 46_CD )_) ,_, A71V/T_NP (_( 15_CD %_NN ;_: 7_CD of_IN 46_CD )_) ,_, V82I_NP (_( 6_CD %_NN ;_: 3_CD of_IN 46_CD )_) ,_, and_CC L10I/V_NP (_( 4_CD %_NN ;_: 2_CD of_IN 46_CD )_) ._SENT Single_JJ amino_NN acid_NN mutations_NNS were_VBD identified_VBN in_IN 23_CD (_( 50_CD %_NN )_) of_IN the_DT 46_CD PR_NP sequences_NNS ,_, whereas_IN 34_CD %_NN of_IN sequences_NNS harbored_VBD dual_JJ (_( 30_CD %_NN ;_: 14_CD of_IN 46_CD )_) ,_, triple_JJ (_( 2_CD %_NN ;_: 1_CD of_IN 46_CD )_) and_CC quadruple_JJ (_( 2_CD %_NN )_) PI-associated_JJ substitutions_NNS ._SENT To_TO search_VB for_IN changes_NNS over_IN time_NN in_IN the_DT PI-associated_JJ mutations_NNS among_IN the_DT subtype-B_NN infections_NNS in_IN Brazil_NP ,_, PI-associated_JJ substitutions_NNS found_VBN in_IN 41_CD PR_NP sequences_NNS collected_VBN in_IN 1998_CD were_VBD compared_VBN with_IN those_DT found_VBN in_IN 38_CD sequences_NNS collected_VBN from_IN drug-naive_JJ individuals_NNS in_IN 1987_CD to_TO 1994_CD ._SENT There_EX were_VBD no_DT primary_JJ PI-associated_JJ mutations_NNS in_IN PR_NP sequences_NNS in_IN either_DT collection_NN ,_, and_CC PI_NP secondary_JJ mutational_JJ patterns_NNS were_VBD similar_JJ in_IN the_DT two_CD sets_NNS ._SENT However_RB ,_, the_DT frequency_NN of_IN isolates_NNS harboring_VBG PI-associated_JJ secondary_JJ resistance_NN mutations_NNS was_VBD higher_JJR (_( 0.025_CD <_SYM P_NN <_SYM 0.05_CD by_IN a_DT one-tailed_JJ chi2_NN test_NN )_) in_IN the_DT 1998_CD data_NNS set_VBN (_( 85_CD %_NN )_) than_IN in_IN the_DT 1987-to-1994_JJ collection_NN (_( 66_CD %_NN )_) ._SENT This_DT finding_NN possibly_RB reflects_VBZ a_DT natural_JJ evolution_NN of_IN the_DT PR_NP gene_NN over_IN time_NN rather_RB than_IN selection_NN of_IN HIV-1_JJ strains_NNS harboring_VBG PI-associated_JJ substitutions_NNS resulting_VBG from_IN PI_NP treatment_NN in_IN Brazil_NP ._SENT FIG._NN 1_CD ._SENT |_SYM Percentages_NP of_IN PR_NP subtype-B_NN sequences_NNS with_IN PI-associated_JJ secondary_JJ amino_NN acid_NN mutations_NNS at_IN two_CD different_JJ time_NN points_NNS ._SENT Percentages_NNS of_IN PR_NP subtype-B_NN sequences_NNS with_IN PI-associated_JJ secondary_JJ amino_NN acid_NN mutations_NNS at_IN two_CD different_JJ time_NN points_NNS ._SENT The_DT number_NN of_IN sequences_NNS with_IN the_DT indicated_JJ mutation_NN is_VBZ given_VBN inside_RB or_CC directly_RB above_IN each_DT bar_NN ._SENT Statistical_JJ significances_NNS of_IN the_DT differences_NNS (_( by_IN a_DT one-tailed_JJ Fisher_NP or_CC chi2_JJ test_NN )_) are_VBP given_VBN above_IN the_DT bars_NNS ._SENT Total*_NP ,_, total_JJ numbers_NNS of_IN sequences_NNS with_IN at_IN least_JJS one_CD mutation_NN ._SENT The_DT results_NNS presented_VBN in_IN Table_NP indicated_VBD that_DT none_NN of_IN the_DT 47_CD RT_NP sequences_NNS from_IN the_DT 1998_CD collection_NN harbored_VBD primary_JJ mutations_NNS associated_VBN with_IN resistance_NN to_TO FDA-approved_JJ NRTIs_NP and_CC only_RB one_PP had_VBD the_DT secondary_JJ mutation_NN V118I_NP (_( 2_CD %_NN ;_: 1_CD of_IN 47_CD )_) ._SENT Analysis_NN of_IN FDA-approved_JJ NNRTI-associated_JJ mutations_NNS indicated_VBD that_IN neither_DT primary_JJ nor_CC secondary_JJ substitutions_NNS were_VBD present_JJ in_IN 47_CD RT_NP sequences_NNS analyzed_VBD ._SENT Our_PP$ findings_NNS are_VBP in_IN agreement_NN with_IN the_DT low_JJ proportion_NN of_IN drug-naive_JJ subjects_NNS infected_VBN with_IN viruses_NNS harboring_VBG primary_JJ drug-resistant_JJ mutations_NNS in_IN Venezuela_NP and_CC Argentina_NP but_CC in_IN contrast_NN with_IN reports_NNS of_IN the_DT presence_NN of_IN HIV-1_JJ strains_NNS carrying_VBG primary_JJ mutations_NNS in_IN drug-naive_JJ individuals_NNS in_IN North_NP America_NP [_SYM ,_, ,_, ,_, ,_, ;_: Little_JJ et_FW al._FW ,_, Antivir_NN ._SENT Ther_NN ._SENT 6(Suppl_JJ ._SENT 1):21_JJ ,_, 2001_CD ]_SYM and_CC Europe_NP (_( ,_, ,_, ,_, ,_, ;_: Chaix_NP et_FW al._FW ,_, Program_NP Abstr_NP ._SENT 8th_JJ Conf_NP ._SENT Retroviruses_NNS Opportunistic_JJ Infections_NNS ,_, abstr_NN ._SENT 755_CD ,_, 2001_CD ;_: Yerly_NP et_FW al._FW ,_, Program_NP Abstr_NP ._SENT 8th_JJ Conf_NP ._SENT Retroviruses_NNS Opportunistic_JJ Infections_NNS ,_, abstr_NN ._SENT 754_CD ,_, 2001_CD )_) who_WP are_VBP infected_VBN with_IN subtype-B_NN viruses_NNS ._SENT A_DT few_JJ factors_NNS may_MD contribute_VB to_TO these_DT differences_NNS ,_, such_JJ as_IN the_DT length_NN of_IN time_NN under_IN drug_NN selective_JJ pressures_NNS and_CC the_DT time_NN period_NN between_IN primary_JJ infection_NN and_CC sampling_NN ._SENT In_IN addition_NN to_TO specific_JJ mutations_NNS known_VBN to_TO contribute_VB to_TO RTI_NP resistance_NN ,_, a_DT few_JJ unusual_JJ changes_NNS were_VBD observed_VBN in_IN RT_NP sequences_NNS at_IN both_CC the_DT NRTI_NP resistance-associated_JJ sites_NNS (_( E44G_NP [_SYM 6.4_CD %_NN ]_SYM ,_, K70I_NP [_SYM 2.2_CD %_NN ]_SYM ,_, V75L_NP [_SYM 2.2_CD %_NN ]_SYM ,_, Q151K_NP [_SYM 2.2_CD %_NN ]_SYM ,_, T215P/S_NPS [_SYM 8.5_CD %_NN ]_SYM ,_, and_CC K219P/R/T_NP [_SYM 8.5_CD %_NN ]_SYM )_) and_CC the_DT NNRTI_NP resistance-associated_JJ positions_NNS (_( A98S_NP [_SYM 4.2_CD %_NN ]_SYM and_CC V106/I/L_NP [_SYM 13_CD %_NN ]_SYM )_) ._SENT Of_IN note_NN ,_, recent_JJ data_NNS indicate_VBP that_IN the_DT T215S_NP substitution_NN ,_, which_WDT was_VBD found_VBN in_IN two_CD of_IN our_PP$ RT_NP sequences_NNS ,_, is_VBZ responsible_JJ for_IN a_DT more-rapid_JJ emergence_NN of_IN zidovudine_NP (_( AZT_NP )_) resistance_NN in_IN vitro_NN ,_, and_CC it_PP is_VBZ speculated_VBN that_IN this_DT selection_NN could_MD also_RB take_VB place_NN in_IN vivo_JJ (_( J._NP G._NP Garcia-Lerma_NP ,_, S._NP Nidtha_NP ,_, K._NP Blumoff_NP ,_, H._NP Weinstock_NP ,_, and_CC W._NP Heneine_NP ,_, Program_NP Abstr_NP ._SENT 5th_JJ Int_NP ._SENT Workshop_NN HIV_NP Drug_NP Resistance_NP Treatment_NP Strategies_NP ,_, abstr_NP ._SENT 21_CD and_CC 22_CD ,_, 2001_CD )_) ._SENT Sixteen_CD isolates_NNS that_WDT represented_VBD distinct_JJ phylogenetic_JJ subtypes_NNS and_CC a_DT variety_NN of_IN genotypic_JJ PI-_NN and_CC RTI-associated_JJ mutation_NN patterns_NNS were_VBD selected_VBN for_IN in_IN vitro_NN evaluation_NN of_IN susceptibility_NN to_TO the_DT PIs_NP (_( saquinavir_NN [_SYM SQV_NP ]_SYM ,_, ritonavir_NN [_SYM RTV_NP ]_SYM ,_, indinavir_NN [_SYM IDV_NP ]_SYM ,_, nelfinavir_NN [_SYM NFV_NP ]_SYM ,_, and_CC amprenavir_NNS [_SYM APV_NP ]_SYM )_) ,_, NRTIs_NP (_( AZT_NP ,_, lamivudine_NP [_SYM 3TC_NN ]_SYM ,_, didanosine_NN [_SYM ddI_NN ]_SYM ,_, zalcitibine_NN [_SYM ddC_NN ]_SYM ,_, stavudine_NP [_SYM d4T_NN ]_SYM ,_, and_CC abacavir_NNS [_SYM ABV_NP ]_SYM )_) ,_, and_CC NNRTIs_NP (_( nevirapine_NN [_SYM NVP_NP ]_SYM ,_, delavirdine_NN [_SYM DLV_NP ]_SYM ,_, and_CC efavirenz_NNS [_SYM EFV_NP ]_SYM )_) by_IN using_VBG VIRCO_NP 's_POS Antivirogram_NN assay_NN ._SENT This_DT phenotypic_JJ analysis_NN revealed_VBD moderate_JJ resistance_NN to_TO NFV_NP in_IN only_RB one_CD strain_NN (_( 98BRVM15_NN )_) ,_, which_WDT harbored_VBD quadruple_JJ PI-associated_JJ secondary_JJ mutations_NNS :_: 36I_JJ 63P_JJ 71V_NP 77I_NP ._SENT Three_CD strains_NNS (_( 98BRVM15_NP ,_, 98BRVM16_NN ,_, and_CC 98BRVM85_NN )_) revealed_VBD moderate_JJ resistance_NN (_( 4.0-_CD to_TO 6.5-fold_NN )_) to_TO ddI_NNS ._SENT Finally_RB ,_, strain_NN 98BRVM58_NN showed_VBD levels_NNS of_IN resistance_NN above_IN the_DT biological_JJ cutoff_NN value_NN for_IN NVP_NP (_( 8.0-fold_NN )_) ._SENT The_DT levels_NNS of_IN resistance_NN above_IN cutoff_NN values_NNS for_IN ddI_NP and_CC NVP_NP observed_VBD in_IN these_DT samples_NNS could_MD not_RB be_VB easily_RB explained_VBN by_IN the_DT respective_JJ viral_JJ genotypes_NNS ,_, which_WDT lacked_VBD primary_JJ resistance_NN mutations_NNS ._SENT It_PP is_VBZ likely_JJ that_IN mutations_NNS L283I_NP ,_, Y318F_NP ,_, and_CC P236L_NP (_( codons_NNS that_WDT were_VBD outside_IN the_DT RT_NP fragment_NN analyzed_VBD in_IN this_DT study_NN )_) ,_, in_IN combination_NN with_IN other_JJ ,_, as_RB yet_RB unidentified_JJ NNRTI_NP mutations_NNS ,_, are_VBP responsible_JJ for_IN moderate_JJ resistance_NN ._SENT For_IN example_NN ,_, the_DT dual_JJ mutations_NNS I135T_NP L283I_NP were_VBD recently_RB found_VBN to_TO be_VB associated_VBN with_IN intermediate_JJ resistance_NN to_TO NVP_NP and_CC DLV_NP ._SENT Our_PP$ study_NN showed_VBD that_IN isolate_NN 98BMVM58_NN ,_, which_WDT has_VBZ shown_VBN resistance_NN to_TO NVP_NP ,_, had_VBD the_DT I135T_NP substitution_NN ._SENT Also_RB ,_, it_PP is_VBZ possible_JJ that_IN the_DT presence_NN of_IN leucine_NN instead_RB of_IN valine_NN at_IN codon_NN 106_CD could_MD contribute_VB to_TO the_DT NVP_NP resistance_NN of_IN this_DT strain_NN ._SENT Observed_JJ discrepancies_NNS between_IN genotype_NN and_CC phenotype_NN ,_, especially_RB with_IN regard_NN to_TO intermediate_JJ resistance_NN to_TO NNRTIs_NP ,_, have_VBP been_VBN reported_VBN previously_RB ._SENT TABLE_NN 2_CD |_SYM Phenotypic_JJ and_CC genotypic_JJ profiles_NNS of_IN selected_JJ samples_NNS This_DT study_NN provides_VBZ the_DT most_RBS comprehensive_JJ evaluation_NN to_TO date_VB of_IN both_CC the_DT genetic_JJ diversity_NN and_CC the_DT PR_NP and_CC RT_NP drug-resistant_JJ patterns_NNS in_IN treatment-naive_JJ HIV-1-infected_JJ individuals_NNS after_IN the_DT introduction_NN of_IN free_JJ access_NN to_TO HAART_NP in_IN Brazil_NP in_IN 1996_CD ._SENT Our_PP$ findings_NNS showing_VBG a_DT lack_NN of_IN resistant_JJ strains_NNS circulating_VBG in_IN drug-naive_JJ subjects_NNS do_VBP not_RB support_VB the_DT need_NN for_IN genotyping_NN before_IN ARV_NP therapy_NN initiation_NN ._SENT The_DT nucleotide_NN sequences_NNS of_IN the_DT HIV-1_NP PR_NP and_CC RT_NP genes_NNS sequenced_JJ in_IN this_DT study_NN have_VBP been_VBN assigned_VBN GenBank_NP accession_NN numbers_VBZ to_TO ._SENT 